[ad_1]
The “Road to Cure” campaign to fight colorectal cancer in December 2021 will be awarded to selected winners of the new “Research Advocacy Excellence Return Screening Award”
Fight colorectal cancer (Fight CRC), the leading colorectal cancer (CRC) patient advocacy organization in the United States, and Guardant Health, Inc. (NASDAQ:Growth hormone) Is a leader in precision oncology and will recognize clinical researchers and advocates who have demonstrated outstanding leadership in getting people back to routine colorectal cancer screening during the pandemic.
This press release features multimedia. View the full version here: https://www.businesswire.com/news/home/20210720005424/en/
The award is called the “Research Advocacy Excellence Regression Screening Award” and will recognize the important contributions of Fight CRC research advocates and key researchers who participated in Guardant Health’s ECLIPSE trial, which is an evaluation of the use of blood tests for screening Of clinical studies for colorectal cancer. The selected winners of this award will be awarded at the Fight CRC “Road to Healing” event in December 2021. It is worth noting that this year’s event will convene a group of research and advocacy experts whose task is to develop a path to cure colorectal cancer. The framework will be shared with the National Cancer Institute (NCI) and the National Institutes of Health (NIH) to require action to help achieve this goal.
“The COVID-19 pandemic has forced colorectal cancer screening in certain communities to stagnate. The data shows a significant decline in 2020 compared to the same point in time a few years before the pandemic,” said Anjee Davis, President of Fight CRC. “Despite these challenges, the Fight CRC research advocates and key researchers participating in the ECLIPSE trial have made tremendous efforts to continue to advance needles to improve colorectal cancer screening rates and ultimately save lives. Fight CRC and Guardant Health have always been Focus Our common goal is to get people to go back to routine cancer screenings after the pandemic.”
This Solar eclipse test, A study of more than 10,000 patients is currently underway to evaluate the performance of Guardant Health blood tests to detect colorectal cancer in the average-risk adult population.1 in case…
The full story on Benzinga.com
[ad_2]
Source link
